Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. Issue 6 (26th April 2018)

• Record Type: Journal Article
• Authors: Matsuba, Ikuro; Matsuba, Ren; Ishibashi, Shun; Yamashita, Shizuya; Arai, Hidenori; Yokote, Koutaro; Suganami, Hideki; Araki, Eiichi
• Is Part Of: Journal of diabetes investigation. Volume 9:Issue 6(2018)
• Page Start: 1323
• Page End: 1332
• Publication Date: 2018-04-26
• Subjects: Glucose clamp(s) -- Insulin resistance -- Selective peroxisome proliferator‐activated receptor‐α modulator; Diabetes -- Periodicals; Diabetes -- Research -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1111/jdi.12845
• Languages: English
• ISSNs: 2040-1116

Abstract

Abstract: Aims/Introduction: Pemafibrate is a novel selective peroxisome proliferator‐activated receptor‐α modulator with potent triglyceride‐lowering and high‐density lipoprotein cholesterol‐raising effects. We showed that pemafibrate decreased the homeostatic model assessment for insulin resistance in patients with dyslipidemia. To investigate how pemafibrate improves insulin sensitivity, we used a hyperinsulinemic‐euglycemic clamp technique to determine the splanchnic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. Materials and Methods: A total of 27 patients with hypertriglyceridemia and insulin resistance were randomly assigned to receive pemafibrate (0.4 mg/day, b.i.d.) or placebo treatment for 12 weeks. The hyperinsulinemic‐euglycemic clamp test combined with oral glucose loading was carried out at weeks 0 and 12 to evaluate the splanchnic and peripheral glucose uptake. Results: Pemafibrate, but not the placebo, significantly increased the splanchnic glucose uptake rate from baseline (19.6 ± 5.9% with P = 0.005 and 2.1 ± 7.4% with P = 0.78, respectively), although no significant difference between the groups was observed ( P = 0.084). Conversely, peripheral glucose uptake rate was not significantly altered. Pemafibrate, compared with the placebo, significantly decreased plasma triglycerides (−61.4 ± 16.4% vs −2.5 ± 41.4%, P = 0.001), free fatty acids (−24.8 ± 23.2% vs 2.0 ± 26.8%, P = 0.016) and gamma‐glutamyl transpeptidase (−30 ± 46 vs 10 ± 19 U/L, P = 0.009) levels, and significantly increased fibroblast growth factor 21 (457.7 ± 402.1 vs −41.7 ± 37.4 pg/mL, P = 0.007) levels. Conclusions: Pemafibrate increased splanchnic glucose uptake from baseline in patients with hypertriglyceridemia. Abstract : The hyperinsulinemic–euglycemic clamp test combined with oral glucose loading was performed to evaluate the splanchnic and peripheral glucose uptake. Pemafibrate, but not placebo, significantly increased the splanchnic glucose uptake rate from the baseline (19.6 ± 5.9% with P = 0.005 and 2.1 ± 7.4% with P = 0.78, respectively).